Table 2.
Serial analysis of BMMNC from AA patients with small monosomy 7 clones exposed in vitro to GCSF
| Patient no. | −18 mo NT, % | −18 mo + GCSF, % | −12 mo NT, % | −12 mo+ GCSF, % | −6 mo NT, % | −6 mo + GCSF, % | 0 mo NT, % |
|---|---|---|---|---|---|---|---|
| 29 | 5 | 7 | 4 | 7 | 10 | 30 | 60 |
| 30 | 6 | 10 | 7 | 14 | 12 | 45 | 46 |
| 31 | 12 | 23 | 10 | 16 | 18 | 35 | 38 |
| 32 | ND | ND | ND | ND | 24 | 41 | 53 |
Frozen samples from AA patients were obtained before the development of any clinical cytogenetic abnormality BMMNC cultured with GCSF. Results are shown as percentage of monosomy 7 cells. Time 0 is when monosomy 7 was clinically first evident on routine cytogenetics. NT, not treated with GCSF; ND, not done.